CMS Acquires China Rights to Seven Generic Drugs from India’s Sun Pharma

Sun Pharma
Published on: August 20, 2019
Author: Amy Liu

Shenzhen’s China Medical System acquired China rights to seven generic drugs from India’s Sun Pharma. The seven drugs were not identified, but Sun Pharma said they have China market revenues of $1 billion annually. Two months ago, CMS in-licensed two other Sun Pharma products, a treatment for dry eye and a biologic treatment for psoriasis. Sun Pharma is one of several Indian drug companies that are now bringing their products to China, usually by forming relationships with China companies. The financial details of the agreement were not disclosed. Source: China Biotoday

Biotechnology Genomics Healthcare Services Life Science